Datroway® Recommended for EU Approval as First-Line TNBC Treatment
Event summary
- Datroway® (datopotamab deruxtecan) recommended for EU approval as first-line treatment for metastatic triple-negative breast cancer (TNBC) patients ineligible for immunotherapy.
- Positive opinion based on TROPION-Breast02 trial results showing a 5.0-month improvement in median overall survival vs. chemotherapy.
- European Commission to review recommendation, with final decision pending.
- Datroway is jointly developed by Daiichi Sankyo and AstraZeneca.
The big picture
This recommendation underscores the growing role of antibody-drug conjugates (ADCs) in oncology, particularly for aggressive cancers like TNBC with limited treatment options. The approval would expand Daiichi Sankyo's presence in the EU market, reinforcing its collaboration with AstraZeneca in developing next-generation cancer therapies.
What we're watching
- Regulatory Timing
- The pace at which the European Commission grants final approval will determine Datroway's market entry timeline in the EU.
- Commercial Strategy
- How Daiichi Sankyo and AstraZeneca position Datroway against existing TNBC treatments, particularly for patients ineligible for immunotherapy.
- Pipeline Expansion
- The progress of additional trials evaluating Datroway across multiple cancers, including NSCLC and urothelial cancer.
Related topics